Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000221044 | SCV000277997 | uncertain significance | Hereditary cancer-predisposing syndrome | 2015-08-26 | criteria provided, single submitter | clinical testing | The p.R1649T variant (also known as c.4946G>C and 5065G>C), located in coding exon 14 of the BRCA1 gene, results from a G to C substitution at nucleotide position 4946. The arginine at codon 1649 is replaced by threonine, an amino acid with similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. To date, this alteration has been detected with an allele frequency of approximately 0.001% (greater than 150,000 alleles tested) in our clinical cohort. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of p.R1649T remains unclear. |
| Brotman Baty Institute, |
RCV001077852 | SCV001243847 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro |